Mission: International aids vaccine initiative (iavi) is a global initiative dedicated to ensure the development of safe, effective, accessible, preventive hiv vaccines for use throughout the world.
Programs: Research and development - implementing a focused and nimble research and development program that catalyzes innovation and action by multiple stakeholders and helps drive the field. Iavi's r&d team designs and develops hiv vaccine candidates, and conducts vaccine trials and related epidemiological research, in partnership with more than 50 academic, biotechnology, pharmaceutical and governmental institutions. Iavi r&d prioritizes two primary approaches to preventing hiv infection: engaging the immune system to block infection, and training it to recognize and destroy cells already infected by hiv. Hiv vaccine candidates are put through a rigorous and lengthy process of clinical evaluation to establish their safety and efficacy. Iavi and its partners subscribe to the highest scientific and ethical standards for conducting trials of hiv vaccine candidates, one that emphasizes protecting the rights, well-being and dignity of trial volunteers. Iavi and its partners have so far developed and advanced 15 vaccine candidates into 27 early-stage human trials in 11 countries in asia, africa, europe and north america. Iavi and its partners have established a network of sophisticated laboratories and clinical research centers in asia, africa, europe and north america. Iavi also has launched research consortia to address the major scientific problems of hiv vaccine development and boost the number and quality of novel vaccine candidates evaluated in clinical trials. A major portion of the vaccine research that iavi supports is conducted in developing countries, where 95% of all new hiv infections occur. Iavi prioritizes building technical and scientific capacity in these countries.
advocacy, policy and communications - ensuring supportive national, regional and global political, economic and societal environments that drive the fastest possible development of an aids vaccine that will be effective for and accessible to the people most in need, as a critical element of a comprehensive response to end aids. Work with advocates, researchers, activists and representatives of the communities hardest hit by hiv/aids to raise awareness as well as strengthen local advocacy capacity and research preparedness.